Emily H Y Cheng

Title: The Innovative Contributions of Emily H Y Cheng

Introduction

Emily H Y Cheng is a notable inventor based in Ladue, MO (US). He has made significant contributions to the field of protease research, particularly through his innovative work on Taspase1. His research has implications for cancer treatment, specifically leukemia.

Latest Patents

Emily H Y Cheng holds a patent titled "Inhibitors of Taspase1 protease activity." This patent describes a novel protease, Taspase1, which is involved in the cleavage of the myeloid/lymphoid or mixed-lineage leukemia (MLL) protein. The proper regulation of HOX genes is essential for various biological processes, and Taspase1 plays a critical role in this regulation. The patent also outlines diagnostic methods utilizing Taspase1, as well as inhibitors that can be used to treat cancers, including leukemia, in affected subjects. He has 1 patent to his name.

Career Highlights

Emily H Y Cheng is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance research in cancer biology. His work has garnered attention for its potential to improve therapeutic strategies for leukemia and other cancers.

Collaborations

Some of his notable coworkers include James J D Hsieh and Stanley J Korsmeyer, who have collaborated with him on various research projects.

Conclusion

Emily H Y Cheng's innovative work in the field of protease research and his contributions to cancer treatment highlight the importance of scientific advancements in medicine. His patent on Taspase1 inhibitors represents a significant step forward in the fight against leukemia.